Data on Gilead's HIV capsid inhibitor lenacapavir are truly extraordinary. Zero (!!!) infections among the women who received this potential new form of PrEP. Now all hands on deck are needed to map out its eventual rollout. My latest (gift link):
www.bloomberg.com/opinion/arti...
